Rafe Shellooe

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index4.6kcitations33works2.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(11), Melanoma and MAPK Pathways(9), Ubiquitin and proteasome pathways(5), Chronic Lymphocytic Leukemia Research(5), Chronic Myeloid Leukemia Treatments(5)

Publications33 total

Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC
Cancer Research·2024· 2 cited
Abstract C085: OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription, including MYC, in mCRPC
Molecular Cancer Therapeutics·2023
Supplementary Figures & Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Methods from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Supplementary Methods from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Figures & Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors
JAMA Oncology·2021· 38 citedOpen Access
The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma
JCI Insight·2018· 35 citedOpen Access
Abstract 2515: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and BRAF-inhibitor resistance
Cancer Research·2018
Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.
Journal of Clinical Oncology·2018· 12 cited
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Cancer Discovery·2018· 135 citedOpen Access
Abstract 3332: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition
Cancer Research·2017
Abstract 1885: Integrated epigenomic profiling reveals widespread demethylation in melanoma and points to the role of CSF1R-RUNX1 axis in resistance against BRAF inhibition
Cancer Research·2016
RAF inhibitors that evade paradoxical MAPK pathway activation
Nature·2015· 374 cited
page 1 of 2Next →

Frequent Co-authors

Gideon Bollag(31), Gaston Habets(31), Bernice Matusow(24), Prabha N. Ibrahim(22), Wayne Spevak(21), Brian L. West(21), Jiazhong Zhang(19), Garson Tsang(19), Adhirai Marimuthu(17), Heidi Carias(16), Hoa Nguyen(14), Elizabeth A. Burton(13), Marika Nespi(13), James Tsai(11), Todd Ewing(11), Ben Powell(10), Laura Sanftner(10), Paul Severson(10), Songyuan Shi(10), Jeffrey A. Sosman(8)